Cargando…
Smart Design of Mitochondria-Targeted and ROS-Responsive CPI-613 Delivery Nanoplatform for Bioenergetic Pancreatic Cancer Therapy
Mitochondria, as the powerhouse of most cells, are not only responsible for the generation of adenosine triphosphate (ATP) but also play a decisive role in the regulation of apoptotic cell death, especially of cancer cells. Safe potential delivery systems which can achieve organelle-targeted therapy...
Autores principales: | Zhang, Yi-Mei, Xia, Meng, Ao, Rui, Gao, Li-Xia, Tang, Yan, Huang, Jiu-Hong, Luo, Ya-Fei, Chen, Zhong-Zhu, Wang, Bo-Chu, Huang, Zheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617807/ https://www.ncbi.nlm.nih.gov/pubmed/34835640 http://dx.doi.org/10.3390/nano11112875 |
Ejemplares similares
-
Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism
por: Kumstel, Simone, et al.
Publicado: (2022) -
Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy
por: Khan, Husain Yar, et al.
Publicado: (2022) -
CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling
por: Gao, Lixia, et al.
Publicado: (2020) -
A phase 1 study of first-in-class agent CPI-613 in combination with FOLFIRINOX for metastatic pancreatic cancer
por: Alistar, Angela, et al.
Publicado: (2017) -
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
por: Bellio, Chiara, et al.
Publicado: (2019)